About ALS2 C-terminal-like protein
ALS2 C-terminal-like protein (ALS2CL) is a protein
from Homo sapiens identified by UniProt accession
Q60I27, 953 residues long.
MolForge cross-references it against 0 known binders and
21 disease associations.
Target properties
| Protein name | ALS2 C-terminal-like protein |
|---|
| UniProt accession | Q60I27 |
|---|
| Gene | ALS2CL |
|---|
| Organism | Homo sapiens |
|---|
| Length | 953 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (21)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- lean body mass · score 0.31
- fat body mass · score 0.28
- total blood protein measurement · score 0.25
- appendicular lean mass · score 0.09
- isolated asymptomatic elevation of creatine phosphokinase · score 0.07
- pentosuria · score 0.05
- body mass index · score 0.04
- reaction time measurement · score 0.02
- macrophage inflammatory protein 1b measurement · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q60I27-F1 | alphafold | PREDICTED | 80.29 | — |
Amino-acid sequence (953 residues)
MCNPEEAALL RLEEVFSATL AHVNSLVLQP LLPAAPDPSD PWGRECLRLL QQLHKSSQQL WEVTEESLHS LQERLRYPDS TGLESLLLLR GADRVLQAHI EYIESYTSCM VVQAFQKAAK RRSEYWRGQR KALRQLLSGV SSEGSVGASL GQALHQPLAH HVQQYVLLLL SLGDTIGEHH PTRELVVNAV TLFGNLQSFM KQELDQAVAT QALWHTLRGR LRDVLCTPAH RLLQDSQDVP VTVAPLRAER VLLFDDALVL LQGHNVHTFD LKLVWVDPGQ DGCTFHLLTP EEEFSFCAKD SQGQAVWQWK VTWAVHQALH GKKDFPVLGA GLEPSQPPDC RCAEYTFQAE GRLCQATYEG EWCRGRPHGK GTLKWPDGRN HVGNFCQGLE HGFGIRLLPQ ASEDKFDCYK CHWREGSMCG YGICEYSTDE VYKGYFQEGL RHGFGVLESG PQAPQPFRYT GHWERGQRSG YGIEEDGDRG ERYIGMWQAG QRHGPGVMVT QAGVCYQGTF QADKTVGPGI LLSEDDSLYE GTFTRDLTLM GKGKVTFPNG FTLEGSFGSG AGRGLHTQGV LDTAALPPDP SSTCKRQLGV GAFPVESRWQ GVYSPFRDFV CAGCPRDLQE ALLGFDVQSS RELRRSQDYL SCERTHPEDS VGSMEDILEE LLQHREPKAL QLYLRKALSN SLHPLGKLLR TLMLTFQATY AGVGANKHLQ ELAQEEVKQH AQELWAAYRG LLRVALERKG QALEEDEDTE TRDLQVHGLV LPLMLPSFYS ELFTLYLLLH EREDSFYSQG IANLSLFPDT QLLEFLDVQK HLWPLKDLTL TSNQRYSLVR DKCFLSATEC LQKIMTTVDP REKLEVLERT YGEIEGTVSR VLGREYKLPM DDLLPLLIYV VSRARIQHLG AEIHLIRDMM DPNHTGGLYD FLLTALESCY EHIQKEDMRL HRLPGHWHSR ELW
Explore ALS2 C-terminal-like protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets